SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
March 11, 2024
Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
Resomelagon (AP1189)
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
-
July 1, 2024 Non RegulatorySynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
-
May 31, 2024 RegulatoryBulletin from the annual general meeting 2024 in SynAct Pharma AB
-
May 31, 2024 RegulatorySynAct Pharma publishes Q1 2024 interim results
A MESSAGE FROM OUR CEO
“I feel confident that the company now has the right team and plan in place to put SynAct back on the right path.”